shutterstock-139528685-web
GlebStock / Shutterstock.com
9 December 2014Americas

Sandoz too quick off the mark in Amgen suit: US court

Novartis’s generic arm Sandoz has failed to win a patent case regarding its biosimilar version of Amgen’s psoriasis and arthritis drug Enbrel (etanercept).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
13 August 2019   Sandoz has confirmed that it plans to appeal against a decision that upheld the validity of two of Amgen’s patents for its arthritis treatment Enbrel, effectively blocking the launch of Sandoz’s biosimilar version.